Quantum Cyber N.V.

Listed Company

QUCYCIK 0001874252NasdaqEmerging GrowthPharmaceutical PreparationsP7NLFY ends Dec 31

Period

FY 2025

Revenue

$537.1K

Net Income

$-16.20M

Total Assets

$5.33M

Equity

$641.6K

Shares Out

12.52M

Op. Cash Flow

$-10.98M

Business

MAINZ BIOMED N.V. develops and sells in-vitro diagnostic tests for early detection of cancer, with a focus on colorectal cancer screening. Its main products and offerings include the CE‑IVD certified ColoAlert multitarget stool DNA test, the PancAlert pancreatic cancer test program (stool- and blood-based biomarkers), clinical laboratory services and distribution of IVD kits, including an online store in Germany. Key business activities comprise product development and R&D, clinical laboratory operations, manufacturing and licensing. The company primarily operates in European markets (with a commercial focus on Germany) and distributes to third‑party laboratories and direct consumers through channel partners and online sales.

Summary from filing dated 2025-03-31

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31
Total revenue	537,080	893,991
Cost of revenue	147,288	319,108
Gross profit	389,792	574,883
Sales and marketing	4	7
Research and development	5	6
Research and development related party	54,775	121,249
General and administrative (Note 2)	5	7
Impairment of intangible asset	3	—
Restructuring expense	—	277,160
Total operating expenses	17	19
Loss from operations	−16	−19
Other income	42,180	90,561
Government grant	533,503	46,087
Gain on sale of subsidiary	—	28,328
Change in fair value of convertible debt	21,000	−2
Gain (loss) on sales and disposal of assets	−163,248	46,818
Interest expense	−373,458	−945,545
Other expense	−131,597	−39,817
Total other expense	−71,620	−3
Loss before income tax	−16	−22
Income tax provision	—	—
Net loss	−16	−22
Foreign currency translation adjustment	−69,023	−96,319
Total comprehensive loss	−16	−22
Basic loss per ordinary share (in Dollars per share)	−2.7	−21.91
Diluted loss per ordinary share (in Dollars per share)	−2.7	−21.91
Basic Weighted average number of ordinary shares outstanding (in Shares)	6	985,717
Diluted Weighted average number of ordinary shares outstanding (in Shares)	6	985,717

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Cash	889,091	6	—
Accounts receivable	17,348	33,577	—
Inventories	216,888	372,870	—
Prepaid expenses and other current assets	657,310	1	—
Total current assets	2	8	—
Property and equipment, net	1	1	—
Intangible assets	1	3	—
Right-of-use assets	1	1	—
Total assets	5	14	—
Accounts payable and accrued liabilities (Note 2)	936,440	3	—
Loan payable	183,706	176,814	—
Convertible debt	82,305	1	—
Notes payable - Silent partnership	956,902	1	—
Intellectual property acquisition liability	487,785	—	—
Intellectual property acquisition liability current portion - related party	676,096	690,575	—
Operating lease liabilities - current portion	356,126	264,982	—
Total current liabilities	4	6	—
Operating lease liabilities	992,480	945,203	—
Intellectual property acquisition liability - related party	—	376,096	—
Total liabilities	5	8	—
Ordinary shares, a par value of 0.01, 11.250.000 shares authorized, 9,780,142 and 2,319,353 shares issued and outstanding, respectively	107,820	23,054	—
Additional paid-in capital	106	95	—
Accumulated deficit	−105	−89	—
Accumulated other comprehensive loss	−617,654	−548,631	—
Total shareholders equity	641,600	6	3
Total liabilities and shareholders equity	5	14	—

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31
Share based compensation	1	986,920
Stock option expense (Note 2)	1	−63,117
Depreciation and amortization	615,720	696,629
Impairment loss	3	47,449
Bad debt recovery	—	−11,919
Inventory write down	312,151	186,338
Accretion expense	202,801	157,703
Change in fair value of convertible debt	−21,000	2
Non-cash lease expense	277,036	367,314
Accounts and other receivable, net	114,630	20,554
Accounts receivable - related party	−43,792	−17,238
Inventories	−99,561	29,811
Prepaid expenses and other assets	791,288	109,246
Accounts payable and accrued liabilities (Note 2)	−2	210,017
Accounts payable and accrued expense - related party	3,557	−22,303
Deferred revenue	—	−135,724
Operating lease liabilities	−326,730	−269,016
Net cash used in operating activities	−11	−17
Proceeds from sale of subsidiary - related party	—	32,785
Payment for intangible asset	−700,000	—
Payment for intangible asset-related party	−350,000	−150,000
Purchase of property and equipment	−1,216	−104,949
Proceeds from sales of property and equipment	17,815	23,347
Net cash used in investing activities	−1	−198,817
Sale of ordinary shares, pre-funded warrants, and warrants	8	14
Proceeds from convertible debt	—	4
Repayments of convertible debt	−1	−1
Payments on silent partnerships	−243,405	—
Payments on loan payable	−241,816	−103,799
Net cash provided by financing activities	7	17
Effect of changes in exchange rates	−96,631	−98,269
Net change in cash	−5	−835,255
Interest expense	178,563	150,021
Income tax	—	—
Right-of-use asset additions	312,021	48,272
Acquisition of intangible asset for structured payments	1	—
Issuance of ordinary shares for conversion of debt	—	10
Payable offset by sale of asset	13,680	—
Loan payable for prepaid insurance	240,826	277,289

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro